About TG4010 cancer vaccine
TG4010 (MVA-MUC1-IL2) uses the Modified Vaccinia Ankara virus vector, a poxvirus that combines distinguishing advantages for an optimized systemic vaccination:
- MVA is a highly attenuated strain which has been tested extensively in humans as a smallpox vaccine and is known to strongly stimulate the immune response to antigens.
- MUC1 is a major tumor-associated antigen that provides a viable target for vaccination.
- TG4010 expresses the entire MUC1 gene sequence and has the potential to generate an immune response to all antigenic epitopes of MUC1.
- The sequence coding for the cytokine Interleukin 2 (IL2) is included to help stimulate specific T-cell response.
About previous TG4010 clinical data
Non-controlled Phase II data are available at: http://www.transgene.fr/us/pdf/communique_presse/communiques_divers_2005/PR -U S_17-05-2005_ASCO_POUMON.pdf (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
Transgene is a France-based biopharmaceutical company dedicated to the
development of therapeutic vaccines and immunotherapeutic products in
oncology and infectious diseases. The company has one product which has
completed Phase II trials (TG4001/R3484), two compounds in Phase II trials
(TG4010 and TG1042) and one compound in Phase I studies (TG4040). Transgene
has concluded a strategic partnership agreement with Roche for the
development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated
diseases. Transgene has bio-manufacturing capacities for viral-based
vectors and technologies available for out-licensing. Additional
information about Transgene is available on the Internet at
|SOURCE Transgene S.A.|
Copyright©2008 PR Newswire.
All rights reserved